The global Autogenous Vaccines market was valued at US$ 433 million in 2023 and is anticipated to reach US$ 587.4 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.

Autogenous Vaccines Market

Autogenous vaccines, also called autologous vaccines, autovaccines, “self” or custom vaccines, are vaccines, which prepared by isolation and destruction of microorganisms in infected individuals and used to provide immunity to the same individual. Generally, indications of autogenous vaccines include resistance of pathogenic microorganisms to antibiotic treatment, ineffective therapy or immune response and lack of commercial vaccines.

Global Autogenous Vaccines key players include Boehringer Ingelheim, Vaxxinova, Zoetis, Ceva Biovac, Phibro, etc. Global top five manufacturers hold a share over 50%. America is the largest market, with a share about 45%, followed by Europe and Asia Pacific, total have a share over 50 percent. In terms of product, Poultry is the largest segment, with a share over 50%. And in terms of application, the largest application is Large Farms, followed by Small Farms.

This report aims to provide a comprehensive presentation of the global market for Autogenous Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autogenous Vaccines.

Report Scope

The Autogenous Vaccines market size, estimations, and forecasts are provided in terms of sales volume (M Does) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Autogenous Vaccines market comprehensively. Regional market sizes, concerning products by Obejection, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Autogenous Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Obejection, by Application, and by regions.

Market Segmentation

Scope of Autogenous Vaccines Market Report

Report Metric	Details
Report Name	Autogenous Vaccines Market
Accounted market size in 2023	US$ 433 million
Forecasted market size in 2030	US$ 587.4 million
CAGR	4.4%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Obejection	Poultry Fishes Pigs & Cattle Other
Segment by Application	Large Farms Small Farms
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Boehringer Ingelheim, Vaxxinova, Zoetis, Ceva Biovac, Phibro, Elanco, AniCon Labor GmbH, Cambridge Technologies, AVICARE plus, Genova Labs, Addison Biological Laboratory, ACE Laboratory Services, Deltamune, Dyntec, Hygieia Biological Laboratories
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Obejection, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Autogenous Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Autogenous Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Obejection, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Autogenous Vaccines Market growing?

Ans: The Autogenous Vaccines Market witnessing a CAGR of 4.4% during the forecast period 2024-2030.

What is the Autogenous Vaccines Market size in 2030?

Ans: The Autogenous Vaccines Market size in 2030 will be US$ 587.4 million.

What is the market share of major companies in Autogenous Vaccines Market?

Ans: Global top five manufacturers hold a share over 50%.

What is the Autogenous Vaccines Market share by region?

Ans: America is the largest market, with a share about 45%, followed by Europe and Asia Pacific, total have a share over 50 percent.

Who are the main players in the Autogenous Vaccines Market report?

Ans: The main players in the Autogenous Vaccines Market are Boehringer Ingelheim, Vaxxinova, Zoetis, Ceva Biovac, Phibro, Elanco, AniCon Labor GmbH, Cambridge Technologies, AVICARE plus, Genova Labs, Addison Biological Laboratory, ACE Laboratory Services, Deltamune, Dyntec, Hygieia Biological Laboratories

What are the Application segmentation covered in the Autogenous Vaccines Market report?

Ans: The Applications covered in the Autogenous Vaccines Market report are Large Farms, Small Farms

1 Autogenous Vaccines Market Overview

1.1 Product Overview and Scope of Autogenous Vaccines

1.2 Autogenous Vaccines Segment by Obejection

1.2.1 Global Autogenous Vaccines Market Value Comparison by Obejection (2024-2030)

1.2.2 Poultry

1.2.3 Fishes

1.2.4 Pigs & Cattle

1.2.5 Other

1.3 Autogenous Vaccines Segment by Application

1.3.1 Global Autogenous Vaccines Market Value by Application: (2024-2030)

1.3.2 Large Farms

1.3.3 Small Farms

1.4 Global Autogenous Vaccines Market Size Estimates and Forecasts

1.4.1 Global Autogenous Vaccines Revenue 2019-2030

1.4.2 Global Autogenous Vaccines Sales 2019-2030

1.4.3 Global Autogenous Vaccines Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Autogenous Vaccines Market Competition by Manufacturers

2.1 Global Autogenous Vaccines Sales Market Share by Manufacturers (2019-2024)

2.2 Global Autogenous Vaccines Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Autogenous Vaccines Average Price by Manufacturers (2019-2024)

2.4 Global Autogenous Vaccines Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Autogenous Vaccines, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Autogenous Vaccines, Product Type & Application

2.7 Autogenous Vaccines Market Competitive Situation and Trends

2.7.1 Autogenous Vaccines Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Autogenous Vaccines Players Market Share by Revenue

2.7.3 Global Autogenous Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Autogenous Vaccines Retrospective Market Scenario by Region

3.1 Global Autogenous Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Autogenous Vaccines Global Autogenous Vaccines Sales by Region: 2019-2030

3.2.1 Global Autogenous Vaccines Sales by Region: 2019-2024

3.2.2 Global Autogenous Vaccines Sales by Region: 2025-2030

3.3 Global Autogenous Vaccines Global Autogenous Vaccines Revenue by Region: 2019-2030

3.3.1 Global Autogenous Vaccines Revenue by Region: 2019-2024

3.3.2 Global Autogenous Vaccines Revenue by Region: 2025-2030

3.4 North America Autogenous Vaccines Market Facts & Figures by Country

3.4.1 North America Autogenous Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Autogenous Vaccines Sales by Country (2019-2030)

3.4.3 North America Autogenous Vaccines Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Autogenous Vaccines Market Facts & Figures by Country

3.5.1 Europe Autogenous Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Autogenous Vaccines Sales by Country (2019-2030)

3.5.3 Europe Autogenous Vaccines Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Autogenous Vaccines Market Facts & Figures by Country

3.6.1 Asia Pacific Autogenous Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Autogenous Vaccines Sales by Country (2019-2030)

3.6.3 Asia Pacific Autogenous Vaccines Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Autogenous Vaccines Market Facts & Figures by Country

3.7.1 Latin America Autogenous Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Autogenous Vaccines Sales by Country (2019-2030)

3.7.3 Latin America Autogenous Vaccines Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Autogenous Vaccines Market Facts & Figures by Country

3.8.1 Middle East and Africa Autogenous Vaccines Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Autogenous Vaccines Sales by Country (2019-2030)

3.8.3 Middle East and Africa Autogenous Vaccines Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Obejection

4.1 Global Autogenous Vaccines Sales by Obejection (2019-2030)

4.1.1 Global Autogenous Vaccines Sales by Obejection (2019-2024)

4.1.2 Global Autogenous Vaccines Sales by Obejection (2025-2030)

4.1.3 Global Autogenous Vaccines Sales Market Share by Obejection (2019-2030)

4.2 Global Autogenous Vaccines Revenue by Obejection (2019-2030)

4.2.1 Global Autogenous Vaccines Revenue by Obejection (2019-2024)

4.2.2 Global Autogenous Vaccines Revenue by Obejection (2025-2030)

4.2.3 Global Autogenous Vaccines Revenue Market Share by Obejection (2019-2030)

4.3 Global Autogenous Vaccines Price by Obejection (2019-2030)

5 Segment by Application

5.1 Global Autogenous Vaccines Sales by Application (2019-2030)

5.1.1 Global Autogenous Vaccines Sales by Application (2019-2024)

5.1.2 Global Autogenous Vaccines Sales by Application (2025-2030)

5.1.3 Global Autogenous Vaccines Sales Market Share by Application (2019-2030)

5.2 Global Autogenous Vaccines Revenue by Application (2019-2030)

5.2.1 Global Autogenous Vaccines Revenue by Application (2019-2024)

5.2.2 Global Autogenous Vaccines Revenue by Application (2025-2030)

5.2.3 Global Autogenous Vaccines Revenue Market Share by Application (2019-2030)

5.3 Global Autogenous Vaccines Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Boehringer Ingelheim

6.1.1 Boehringer Ingelheim Corporation Information

6.1.2 Boehringer Ingelheim Description and Business Overview

6.1.3 Boehringer Ingelheim Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Boehringer Ingelheim Autogenous Vaccines Product Portfolio

6.1.5 Boehringer Ingelheim Recent Developments/Updates

6.2 Vaxxinova

6.2.1 Vaxxinova Corporation Information

6.2.2 Vaxxinova Description and Business Overview

6.2.3 Vaxxinova Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Vaxxinova Autogenous Vaccines Product Portfolio

6.2.5 Vaxxinova Recent Developments/Updates

6.3 Zoetis

6.3.1 Zoetis Corporation Information

6.3.2 Zoetis Description and Business Overview

6.3.3 Zoetis Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Zoetis Autogenous Vaccines Product Portfolio

6.3.5 Zoetis Recent Developments/Updates

6.4 Ceva Biovac

6.4.1 Ceva Biovac Corporation Information

6.4.2 Ceva Biovac Description and Business Overview

6.4.3 Ceva Biovac Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Ceva Biovac Autogenous Vaccines Product Portfolio

6.4.5 Ceva Biovac Recent Developments/Updates

6.5 Phibro

6.5.1 Phibro Corporation Information

6.5.2 Phibro Description and Business Overview

6.5.3 Phibro Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Phibro Autogenous Vaccines Product Portfolio

6.5.5 Phibro Recent Developments/Updates

6.6 Elanco

6.6.1 Elanco Corporation Information

6.6.2 Elanco Description and Business Overview

6.6.3 Elanco Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Elanco Autogenous Vaccines Product Portfolio

6.6.5 Elanco Recent Developments/Updates

6.7 AniCon Labor GmbH

6.6.1 AniCon Labor GmbH Corporation Information

6.6.2 AniCon Labor GmbH Description and Business Overview

6.6.3 AniCon Labor GmbH Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.4.4 AniCon Labor GmbH Autogenous Vaccines Product Portfolio

6.7.5 AniCon Labor GmbH Recent Developments/Updates

6.8 Cambridge Technologies

6.8.1 Cambridge Technologies Corporation Information

6.8.2 Cambridge Technologies Description and Business Overview

6.8.3 Cambridge Technologies Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Cambridge Technologies Autogenous Vaccines Product Portfolio

6.8.5 Cambridge Technologies Recent Developments/Updates

6.9 AVICARE plus

6.9.1 AVICARE plus Corporation Information

6.9.2 AVICARE plus Description and Business Overview

6.9.3 AVICARE plus Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.9.4 AVICARE plus Autogenous Vaccines Product Portfolio

6.9.5 AVICARE plus Recent Developments/Updates

6.10 Genova Labs

6.10.1 Genova Labs Corporation Information

6.10.2 Genova Labs Description and Business Overview

6.10.3 Genova Labs Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Genova Labs Autogenous Vaccines Product Portfolio

6.10.5 Genova Labs Recent Developments/Updates

6.11 Addison Biological Laboratory

6.11.1 Addison Biological Laboratory Corporation Information

6.11.2 Addison Biological Laboratory Autogenous Vaccines Description and Business Overview

6.11.3 Addison Biological Laboratory Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Addison Biological Laboratory Autogenous Vaccines Product Portfolio

6.11.5 Addison Biological Laboratory Recent Developments/Updates

6.12 ACE Laboratory Services

6.12.1 ACE Laboratory Services Corporation Information

6.12.2 ACE Laboratory Services Autogenous Vaccines Description and Business Overview

6.12.3 ACE Laboratory Services Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.12.4 ACE Laboratory Services Autogenous Vaccines Product Portfolio

6.12.5 ACE Laboratory Services Recent Developments/Updates

6.13 Deltamune

6.13.1 Deltamune Corporation Information

6.13.2 Deltamune Autogenous Vaccines Description and Business Overview

6.13.3 Deltamune Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Deltamune Autogenous Vaccines Product Portfolio

6.13.5 Deltamune Recent Developments/Updates

6.14 Dyntec

6.14.1 Dyntec Corporation Information

6.14.2 Dyntec Autogenous Vaccines Description and Business Overview

6.14.3 Dyntec Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Dyntec Autogenous Vaccines Product Portfolio

6.14.5 Dyntec Recent Developments/Updates

6.15 Hygieia Biological Laboratories

6.15.1 Hygieia Biological Laboratories Corporation Information

6.15.2 Hygieia Biological Laboratories Autogenous Vaccines Description and Business Overview

6.15.3 Hygieia Biological Laboratories Autogenous Vaccines Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Hygieia Biological Laboratories Autogenous Vaccines Product Portfolio

6.15.5 Hygieia Biological Laboratories Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Autogenous Vaccines Industry Chain Analysis

7.2 Autogenous Vaccines Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Autogenous Vaccines Production Mode & Process

7.4 Autogenous Vaccines Sales and Marketing

7.4.1 Autogenous Vaccines Sales Channels

7.4.2 Autogenous Vaccines Distributors

7.5 Autogenous Vaccines Customers

8 Autogenous Vaccines Market Dynamics

8.1 Autogenous Vaccines Industry Trends

8.2 Autogenous Vaccines Market Drivers

8.3 Autogenous Vaccines Market Challenges

8.4 Autogenous Vaccines Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Cambridge Technologies

AVICARE plus

Genova Labs

Addison Biological Laboratory

ACE Laboratory Services

Deltamune

Dyntec

Hygieia Biological Laboratories

Boehringer Ingelheim

List of Tables

Table 1. Global Autogenous Vaccines Market Value Comparison by Obejection (2024-2030) & (US$ Million)

Table 2. Global Autogenous Vaccines Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Autogenous Vaccines Market Competitive Situation by Manufacturers in 2023

Table 4. Global Autogenous Vaccines Sales (M Does) of Key Manufacturers (2019-2024)

Table 5. Global Autogenous Vaccines Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Autogenous Vaccines Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Autogenous Vaccines Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Autogenous Vaccines Average Price (US$/Does) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Autogenous Vaccines, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Autogenous Vaccines, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Autogenous Vaccines, Product Type & Application

Table 12. Global Key Manufacturers of Autogenous Vaccines, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Autogenous Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autogenous Vaccines as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Autogenous Vaccines Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Autogenous Vaccines Sales by Region (2019-2024) & (M Does)

Table 18. Global Autogenous Vaccines Sales Market Share by Region (2019-2024)

Table 19. Global Autogenous Vaccines Sales by Region (2025-2030) & (M Does)

Table 20. Global Autogenous Vaccines Sales Market Share by Region (2025-2030)

Table 21. Global Autogenous Vaccines Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Autogenous Vaccines Revenue Market Share by Region (2019-2024)

Table 23. Global Autogenous Vaccines Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Autogenous Vaccines Revenue Market Share by Region (2025-2030)

Table 25. North America Autogenous Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Autogenous Vaccines Sales by Country (2019-2024) & (M Does)

Table 27. North America Autogenous Vaccines Sales by Country (2025-2030) & (M Does)

Table 28. North America Autogenous Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Autogenous Vaccines Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Autogenous Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Autogenous Vaccines Sales by Country (2019-2024) & (M Does)

Table 32. Europe Autogenous Vaccines Sales by Country (2025-2030) & (M Does)

Table 33. Europe Autogenous Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Autogenous Vaccines Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Autogenous Vaccines Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Autogenous Vaccines Sales by Region (2019-2024) & (M Does)

Table 37. Asia Pacific Autogenous Vaccines Sales by Region (2025-2030) & (M Does)

Table 38. Asia Pacific Autogenous Vaccines Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Autogenous Vaccines Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Autogenous Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Autogenous Vaccines Sales by Country (2019-2024) & (M Does)

Table 42. Latin America Autogenous Vaccines Sales by Country (2025-2030) & (M Does)

Table 43. Latin America Autogenous Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Autogenous Vaccines Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Autogenous Vaccines Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Autogenous Vaccines Sales by Country (2019-2024) & (M Does)

Table 47. Middle East & Africa Autogenous Vaccines Sales by Country (2025-2030) & (M Does)

Table 48. Middle East & Africa Autogenous Vaccines Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Autogenous Vaccines Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Autogenous Vaccines Sales (M Does) by Obejection (2019-2024)

Table 51. Global Autogenous Vaccines Sales (M Does) by Obejection (2025-2030)

Table 52. Global Autogenous Vaccines Sales Market Share by Obejection (2019-2024)

Table 53. Global Autogenous Vaccines Sales Market Share by Obejection (2025-2030)

Table 54. Global Autogenous Vaccines Revenue (US$ Million) by Obejection (2019-2024)

Table 55. Global Autogenous Vaccines Revenue (US$ Million) by Obejection (2025-2030)

Table 56. Global Autogenous Vaccines Revenue Market Share by Obejection (2019-2024)

Table 57. Global Autogenous Vaccines Revenue Market Share by Obejection (2025-2030)

Table 58. Global Autogenous Vaccines Price (US$/Does) by Obejection (2019-2024)

Table 59. Global Autogenous Vaccines Price (US$/Does) by Obejection (2025-2030)

Table 60. Global Autogenous Vaccines Sales (M Does) by Application (2019-2024)

Table 61. Global Autogenous Vaccines Sales (M Does) by Application (2025-2030)

Table 62. Global Autogenous Vaccines Sales Market Share by Application (2019-2024)

Table 63. Global Autogenous Vaccines Sales Market Share by Application (2025-2030)

Table 64. Global Autogenous Vaccines Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Autogenous Vaccines Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Autogenous Vaccines Revenue Market Share by Application (2019-2024)

Table 67. Global Autogenous Vaccines Revenue Market Share by Application (2025-2030)

Table 68. Global Autogenous Vaccines Price (US$/Does) by Application (2019-2024)

Table 69. Global Autogenous Vaccines Price (US$/Does) by Application (2025-2030)

Table 70. Boehringer Ingelheim Corporation Information

Table 71. Boehringer Ingelheim Description and Business Overview

Table 72. Boehringer Ingelheim Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 73. Boehringer Ingelheim Autogenous Vaccines Product

Table 74. Boehringer Ingelheim Recent Developments/Updates

Table 75. Vaxxinova Corporation Information

Table 76. Vaxxinova Description and Business Overview

Table 77. Vaxxinova Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 78. Vaxxinova Autogenous Vaccines Product

Table 79. Vaxxinova Recent Developments/Updates

Table 80. Zoetis Corporation Information

Table 81. Zoetis Description and Business Overview

Table 82. Zoetis Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 83. Zoetis Autogenous Vaccines Product

Table 84. Zoetis Recent Developments/Updates

Table 85. Ceva Biovac Corporation Information

Table 86. Ceva Biovac Description and Business Overview

Table 87. Ceva Biovac Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 88. Ceva Biovac Autogenous Vaccines Product

Table 89. Ceva Biovac Recent Developments/Updates

Table 90. Phibro Corporation Information

Table 91. Phibro Description and Business Overview

Table 92. Phibro Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 93. Phibro Autogenous Vaccines Product

Table 94. Phibro Recent Developments/Updates

Table 95. Elanco Corporation Information

Table 96. Elanco Description and Business Overview

Table 97. Elanco Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 98. Elanco Autogenous Vaccines Product

Table 99. Elanco Recent Developments/Updates

Table 100. AniCon Labor GmbH Corporation Information

Table 101. AniCon Labor GmbH Description and Business Overview

Table 102. AniCon Labor GmbH Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 103. AniCon Labor GmbH Autogenous Vaccines Product

Table 104. AniCon Labor GmbH Recent Developments/Updates

Table 105. Cambridge Technologies Corporation Information

Table 106. Cambridge Technologies Description and Business Overview

Table 107. Cambridge Technologies Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 108. Cambridge Technologies Autogenous Vaccines Product

Table 109. Cambridge Technologies Recent Developments/Updates

Table 110. AVICARE plus Corporation Information

Table 111. AVICARE plus Description and Business Overview

Table 112. AVICARE plus Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 113. AVICARE plus Autogenous Vaccines Product

Table 114. AVICARE plus Recent Developments/Updates

Table 115. Genova Labs Corporation Information

Table 116. Genova Labs Description and Business Overview

Table 117. Genova Labs Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 118. Genova Labs Autogenous Vaccines Product

Table 119. Genova Labs Recent Developments/Updates

Table 120. Addison Biological Laboratory Corporation Information

Table 121. Addison Biological Laboratory Description and Business Overview

Table 122. Addison Biological Laboratory Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 123. Addison Biological Laboratory Autogenous Vaccines Product

Table 124. Addison Biological Laboratory Recent Developments/Updates

Table 125. ACE Laboratory Services Corporation Information

Table 126. ACE Laboratory Services Description and Business Overview

Table 127. ACE Laboratory Services Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 128. ACE Laboratory Services Autogenous Vaccines Product

Table 129. ACE Laboratory Services Recent Developments/Updates

Table 130. Deltamune Corporation Information

Table 131. Deltamune Description and Business Overview

Table 132. Deltamune Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 133. Deltamune Autogenous Vaccines Product

Table 134. Deltamune Recent Developments/Updates

Table 135. Dyntec Corporation Information

Table 136. Dyntec Description and Business Overview

Table 137. Dyntec Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 138. Dyntec Autogenous Vaccines Product

Table 139. Dyntec Recent Developments/Updates

Table 140. Hygieia Biological Laboratories Corporation Information

Table 141. Hygieia Biological Laboratories Description and Business Overview

Table 142. Hygieia Biological Laboratories Autogenous Vaccines Sales (M Does), Revenue (US$ Million), Price (US$/Does) and Gross Margin (2019-2024)

Table 143. Hygieia Biological Laboratories Autogenous Vaccines Product

Table 144. Hygieia Biological Laboratories Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Autogenous Vaccines Distributors List

Table 148. Autogenous Vaccines Customers List

Table 149. Autogenous Vaccines Market Trends

Table 150. Autogenous Vaccines Market Drivers

Table 151. Autogenous Vaccines Market Challenges

Table 152. Autogenous Vaccines Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Autogenous Vaccines

Figure 2. Global Autogenous Vaccines Market Value Comparison by Obejection (2024-2030) & (US$ Million)

Figure 3. Global Autogenous Vaccines Market Share by Obejection in 2023 & 2030

Figure 4. Poultry Product Picture

Figure 5. Fishes Product Picture

Figure 6. Pigs & Cattle Product Picture

Figure 7. Other Product Picture

Figure 8. Global Autogenous Vaccines Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Autogenous Vaccines Market Share by Application in 2023 & 2030

Figure 10. Large Farms

Figure 11. Small Farms

Figure 12. Global Autogenous Vaccines Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Autogenous Vaccines Market Size (2019-2030) & (US$ Million)

Figure 14. Global Autogenous Vaccines Sales (2019-2030) & (M Does)

Figure 15. Global Autogenous Vaccines Average Price (US$/Does) & (2019-2030)

Figure 16. Autogenous Vaccines Report Years Considered

Figure 17. Autogenous Vaccines Sales Share by Manufacturers in 2023

Figure 18. Global Autogenous Vaccines Revenue Share by Manufacturers in 2023

Figure 19. The Global 5 and 10 Largest Autogenous Vaccines Players: Market Share by Revenue in 2023

Figure 20. Autogenous Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 21. Global Autogenous Vaccines Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Autogenous Vaccines Sales Market Share by Country (2019-2030)

Figure 23. North America Autogenous Vaccines Revenue Market Share by Country (2019-2030)

Figure 24. United States Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Autogenous Vaccines Sales Market Share by Country (2019-2030)

Figure 27. Europe Autogenous Vaccines Revenue Market Share by Country (2019-2030)

Figure 28. Germany Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Autogenous Vaccines Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Autogenous Vaccines Revenue Market Share by Region (2019-2030)

Figure 35. China Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Indonesia Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Thailand Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Malaysia Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Latin America Autogenous Vaccines Sales Market Share by Country (2019-2030)

Figure 45. Latin America Autogenous Vaccines Revenue Market Share by Country (2019-2030)

Figure 46. Mexico Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Brazil Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Argentina Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Middle East & Africa Autogenous Vaccines Sales Market Share by Country (2019-2030)

Figure 50. Middle East & Africa Autogenous Vaccines Revenue Market Share by Country (2019-2030)

Figure 51. Turkey Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Saudi Arabia Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. UAE Autogenous Vaccines Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Global Sales Market Share of Autogenous Vaccines by Obejection (2019-2030)

Figure 55. Global Revenue Market Share of Autogenous Vaccines by Obejection (2019-2030)

Figure 56. Global Autogenous Vaccines Price (US$/Does) by Obejection (2019-2030)

Figure 57. Global Sales Market Share of Autogenous Vaccines by Application (2019-2030)

Figure 58. Global Revenue Market Share of Autogenous Vaccines by Application (2019-2030)

Figure 59. Global Autogenous Vaccines Price (US$/Does) by Application (2019-2030)

Figure 60. Autogenous Vaccines Value Chain

Figure 61. Autogenous Vaccines Production Process

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Distributors Profiles

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions